Get started
VERTEX PHARMACEUTICAL COM STK USD0.01VERTEX PHARMACEUTICAL COM STK USD0.01VERTEX PHARMACEUTICAL COM STK USD0.01

VERTEX PHARMACEUTICAL COM STK USD0.01

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

0QZU trade ideas

VRTX Long Chance on ChannelNASDAQ:VRTX had an ongoing negative Trend since July 2020. It broke the negative Trend 2 days ago. For me its a very good chance and low price for VRTX. strong up move with good volume crossing the negative trend crossed EMA200 and MA200 on daily chart and also on weeky chart still above EMA200 and MA200 on monthly chart still in positive trend since 2008 good position in the market good cashflow for the next years, even if products are failing
NASDAQ:VRTXLong
by JulianRichard11
1
LongAt the close of the GAP. The movement is good. Upside +10%. If there will be a good consolidation - we can look even higher. ❤️ If you find this helpful and want more FREE forecasts in TradingView . . . . . Please show your support back, . . . . . . . . Hit the 👍 LIKE button, . . . . . . . . . . . Drop some feedback below in the comment! ❤️ Your Support is very much 🙏 appreciated!❤️ 💎 Want us to help you become a better Stock trader? Now, It's your turn! Be sure to leave a comment let us know how do you see this opportunity and forecast.
NASDAQ:VRTXLong
by QuantumLabSignals
$VRTX HTF ACB LongWeekly Swing Watchlist Couple great looking opportunities this week, otherwise equities look pretty quite with the broad sell offs we have seen. I am already at full risk after entering two trades last week so I will be sitting on my hands for now. #1 Main Watch $VRTX HTF ACB L Monthly - 0.50 Fib/Decel/50 ema Weekly   - Support/MACD/Double bottom Daily      - Support/MACD/Double bottom/Descending triangle/Decel/Wave 5 completion LTF        - Break out of descending triangle/MACD/Double bottom Entry      - Waiting for 1HR close above 50 ema RR          - 10 (Previous M/W highs) Management - Long term Additionally on Watch: Main: $PENN Daily IBO L Other: 6 stocks on this weeks development needed list 23 stocks on monthly watchlist (mostly in Tech & Health Care sectors) Live Trades: $OEG - Full Risk $AMC - 0.5% Profit locked in $MASS - Full Risk $VUZI - Full Risk $Z - Full Risk
NASDAQ:VRTXLong
by JSiminoski
Pull Back Fishingis could go even lower I suppose. Possible double bottom if it holds. Last candle is a spinning top/a candle of indecision. At this point I would guess it may be undervalued. Just goes down and down and down because I have been watching it for months. Appears the analysts are extremely bearish on VRTX at this time. That is when I stop and take a closer look sometimes, They could be correct for all I know. Sometimes there are things the big guys know that little guys do not know. Like is VRTX going bankrupt or sumpin? I do not think Cystic Fibrosis is going away as it is a genetic disease, but it is also a primarily Caucasian disease? Perhaps just not socially or politically cool right now since it is a primarily Caucasian disease? Perhaps widening their arena to Sickle Cell anemia research and drugs would help the stock price and the analysts would like the stock/but who knows?/just a thought. Tips appreciated. Eventually everything hits a highpoint, and everything reaches a low point. The country I live in, has hit a temporary low point. No recommendation. Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Hide EPS (FWD) 12.28 PE (FWD) 15.32 - Short Interest 1.95% Market Cap $49.65B Volume 1,375,527
NASDAQ:VRTX
by lauralea
2